Alpha-9 Oncology to Present GRPR Imaging Data at EANM 2026

Boston, Massachusetts, U.S., and Vancouver, British Columbia, Canada, October 8, 2026

Alpha-9 Advances GRPR-Targeted PET/CT Imaging

Alpha-9 Oncology’s investigational compound, ⁶⁸Ga-A9-6217, is a GRPR-targeting imaging agent being evaluated for use with positron emission tomography/computed tomography (PET/CT). The approach is designed to visualize tumors expressing GRPR, a molecular target that may help researchers identify patients whose tumors could be suitable for targeted radiopharmaceutical approaches. PET/CT combines molecular imaging with anatomical information, enabling clinicians and researchers to assess the distribution of an imaging agent in the body. In investigational oncology applications, this information can help characterize target expression and support the assessment of whether a tumor may be appropriate for further evaluation with a targeted therapeutic candidate.

Alpha-9 plans to present findings from a Phase 1 study titled A Phase 1 Study Investigating the Safety, Biodistribution, and Dosimetry of [⁶⁸Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors: Case Series of Selected Patients. The oral presentation is listed as OP-877 and is scheduled for Wednesday, October 21, 2026, from 9:45 to 11:15 a.m. Central European Summer Time in Hall C. The study focuses on the safety, distribution of the imaging compound throughout the body, and dosimetry associated with its use. Dosimetry evaluates radiation exposure to tissues and organs, an important consideration in the development of radiopharmaceutical imaging and therapeutic products. The company has announced the presentation but has not included detailed numerical study results in its press release. Therefore, the clinical findings and their implications will need to be assessed from the presented data.

Imaging Supports Targeted Radiotherapeutic Development

Alpha-9 is also evaluating investigational radiotherapeutic candidates designed to target GRPR-expressing tumors. The company is currently enrolling a Phase 1 clinical trial investigating ²²⁵Ac-A9-0642 and ¹⁷⁷Lu-A9-0631 in patients with GRPR-positive solid tumors. The study includes patients with locally advanced, unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer, as well as patients with other solid tumors. The trial is designed to evaluate safety, tolerability, and the recommended dose for expansion of these investigational candidates. Alpha-9 reports that it is using ⁶⁸Ga-A9-6217 for patient selection within this therapeutic development program. The strategy connects molecular imaging with targeted radiotherapeutic research, with the aim of identifying tumors that express the relevant biological target.

The therapeutic candidates use different radioisotopes from the imaging agent. Gallium-68 is used for PET imaging, while actinium-225 and lutetium-177 are being investigated as therapeutic payloads in Alpha-9’s development candidates. Their distinct applications illustrate how a shared molecular target can support both tumor imaging and targeted treatment research.However, the use of an imaging agent for patient selection does not by itself establish that a patient will respond to a therapeutic candidate. Further clinical evaluation is required to determine the relationship between target visualization, treatment selection, safety, and therapeutic outcomes.

EANM 2026 Highlights Radiopharmaceutical Research

The upcoming presentation places Alpha-9’s GRPR imaging program within the broader field of nuclear medicine and precision oncology. Researchers in this area are investigating how molecular targets and radioactive compounds can support more individualized approaches to cancer diagnosis, patient selection, and treatment. Alpha-9 Oncology is a clinical-stage radiotherapeutic company developing targeted treatments for cancer. Its development approach involves optimizing components such as the molecular binder, linker, chelator, and radioisotope payload to influence tumor retention and uptake in healthy organs. The company’s appearance at EANM 2026 will provide an opportunity to share clinical imaging and dosimetry findings with the nuclear medicine community. Further clinical data will be important in establishing the safety, imaging performance, and potential role of ⁶⁸Ga-A9-6217 in patient selection and radiotherapeutic development.

Source: Alpha-9 Oncology press release